Vaccine supply, safety and access at World Vaccine Congress Europe 2026

Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website

42 organizations at World Vaccine Congress Europe 2026 present work in supply, safety & access: 17 public-health and non-profit bodies, 11 vaccine and drug developers, 7 academic bodies and 7 suppliers and service providers. Between them they bring 94 presentations to the program. Most represented: Sanofi (8 on the program), GSK (7 on the program), Moderna (6 on the program). 25 of them have their own page in this guide. As of Sep 26, 2026.

All 251 organizations at World Vaccine Congress Europe 2026 →

Showing 1–7 of 42 organizations

Organization	World Vaccine Congress Europe 2026 Attendance
Sanofi Paris, France
sanofi.com Large pharma Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs.	Talk Mon Oct 19 10:45 mRNA-LNP Platform: Screening, Formulation Optimization and Process Improvements Workshop: Platform Technologies Talk Mon Oct 19 11:30 Immunity Takes Care of Your Skin: The Vaccine Reinventing Acne Treatment Workshop: Cancer & Therapeutic Vaccines Talk Mon Oct 19 14:45 Assessing and Monitoring Vaccine Safety in the AI Era Workshop: Vaccine Safety & Access Talk Mon Oct 19 15:30 Advancing Pandemic Preparedness: Pandemic Flu H5 mRNA program Workshop: Biothreats & Disease X Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. with European Medicines Agency, Vaccines Europe, International Vaccine Institute +4 more Platforms & delivery Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. with PATH, McKinsey & Company, AstriVax Talk Wed Oct 21 13:30 Platform leverage in vaccine development: how diversified technologies and adjuvant innovation are reshaping protection for older adults, Respiratory Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. with GSK, Swedish Medical Products Agency, European Medicines Agency
GSK London, United Kingdom
	Panel Mon Oct 19 12:15 Panel: Building Next-Generation Vaccine Platforms: Innovation, Stability, and Scalability Workshop: Platform Technologies · with CEPI, IAVI, Vaccine Analytics +2 more Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with European Medicines Agency, BioNTech, Gates Medical Research Institute +1 more Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. with UK Health Security Agency (UKHSA), CSL Seqirus, University of Oxford +1 more Talk Wed Oct 21 13:15 Advancing European Competitiveness: Innovation in Vaccine Manufacturing Technology through AI, ML, and Modeling Bioprocess & Manufacturing Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. with London School of Hygiene & Tropical Medicine, Novo Nordisk Foundation Initiative for Vaccines and Immunity, European Vaccine Initiative +2 more Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. with Swedish Medical Products Agency, Sanofi, European Medicines Agency
Moderna Cambridge, MA
	Talk Mon Oct 19 14:00 Workshop Leader Workshop: Vaccine Safety & Access Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with GSK, European Medicines Agency, BioNTech +1 more Talk Mon Oct 19 15:15 Moderna’s Clinical Development of Bundibugyo Ebolavirus Vaccine Workshop: Biothreats & Disease X Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. with UK Health Security Agency (UKHSA), PATH, Erasmus MC +1 more Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. with PATH, Baylor College of Medicine, MHRA +2 more Infectious disease & AMR Talk Wed Oct 21 15:15 Moderna’s Influenza Program Respiratory
PATH Seattle, WA
path.org Public health & non-profit Global health non-profit working on vaccine development, delivery and immunization systems in low- and middle-income countries.	Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. with UK Health Security Agency (UKHSA), Erasmus MC, Moderna +1 more Talk Mon Oct 19 16:30 How vaccine delivery and immunization system criteria shaped the identification and prioritization of novel combination vaccines. Workshop: Vaccine Delivery Talk Mon Oct 19 16:45 Assessing the Value of Combination Vaccines Workshop: Vaccine Delivery Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. with Baylor College of Medicine, MHRA, Moderna +2 more Infectious disease & AMR Talk Wed Oct 21 12:00 Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used? Working Groups · with World Health Organization (WHO), Sciensano Supply, safety & access Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. with Sanofi, McKinsey & Company, AstriVax Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. with World Health Organization (WHO), World Organisation for Animal Health (WOAH), IAVI +2 more
European Commission Brussels, Belgium
commission.europa.eu Public health & non-profit Executive body of the European Union, setting EU health, health-security and veterinary policy.	Panel Tue Oct 20 17:10 One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy How tracking disease in people, animals and the environment together can set vaccine priorities for infections that jump from animals, like bird flu. with Food and Agriculture Organization (FAO), Lyonbiopole, World Organisation for Animal Health (WOAH) +1 more One Health & ecosystems Talk Wed Oct 21 09:00 The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World How governments and industry can keep vaccines flowing fairly across borders in an emergency as countries push to make vaccines at home. with Hilleman Laboratories, Access to Medicine Foundation, UNICEF +2 more Supply, safety & accessBioprocess & manufacturing Talk Wed Oct 21 10:45 Avian Flu (H5N1): Status of Livestock Vaccination Policies in the EU and Global Trade Implication One Health & Veterinary Panel Wed Oct 21 11:00 Panel: Rethinking Livestock Vaccination for Emerging Threats How to speed new livestock vaccines against diseases that can jump to people, weighing approval rules, food safety, trade and funding incentives. with Boehringer Ingelheim, World Organisation for Animal Health (WOAH), SciEthiQ +1 more Talk Wed Oct 21 12:15 Panel: The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs Why low- and middle-income countries are becoming vaccine innovators, not just trial sites, and what funding and regional regulatory cooperation they need. with Hilleman Laboratories, International Vaccine Institute, Luipaard Panel Wed Oct 21 16:00 Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems How Europe can shift vaccine funding from crisis-driven spending to long-term plans, using tools like joint purchasing and advance promises to buy. with University of Groningen, CEPI, UK Department of Health and Social Care +1 more Supply, safety & access
European Medicines Agency Amsterdam, Netherlands
ema.europa.eu Public health & non-profit The European Union's medicines regulator, evaluating and monitoring vaccines and medicines.	Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. with Vaxxcellence, Harvard Medical School, Total Trials Panel Mon Oct 19 14:15 Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up. with Daicel Life Sciences, PharmaJet, LTS Lohmann +2 more Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. with GSK, BioNTech, Gates Medical Research Institute +1 more Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. with Vaccines Europe, International Vaccine Institute, Eli Lilly +4 more Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. with Eli Lilly, Pfizer, CUNY School of Public Health +1 more Supply, safety & access Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. with GSK, Swedish Medical Products Agency, Sanofi
CEPI Oslo, Norway
cepi.net Public health & non-profit Coalition for Epidemic Preparedness Innovations: global partnership funding vaccines against emerging infectious diseases and epidemic threats.	Panel Mon Oct 19 12:15 Panel: Building Next-Generation Vaccine Platforms: Innovation, Stability, and Scalability Workshop: Platform Technologies · with GSK, IAVI, Vaccine Analytics +2 more Talk Tue Oct 20 16:00 Panel: Expanding the Access & Impact of Adjuvants How to get past licensing and approval hurdles so new adjuvants, ingredients that boost a vaccine's immune response, reach more countries. with Baylor College of Medicine, Croda Pharma, Vaccine Formulation Institute +1 more Panel Wed Oct 21 13:30 Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D How studies that deliberately infect volunteers guide vaccine decisions, and what must be in place before using them for new diseases. with International Vaccine Institute, UK Health Security Agency (UKHSA), Centre for Human Drug Research (CHDR) +1 more Panel Wed Oct 21 16:00 Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems How Europe can shift vaccine funding from crisis-driven spending to long-term plans, using tools like joint purchasing and advance promises to buy. with University of Groningen, UK Department of Health and Social Care, European Commission +1 more Supply, safety & access